Alexander Starodub

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond et al. · Journal of Clinical Oncology · 2017 · 386 citations

Breast Oncology, Medicine, Antibody-drug Conjugate +13

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio et al. · Annals of Oncology · 2021 · 349 citations

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Alexander Starodub, Allyson J. Ocean, Manish A. Shah et al. · Clinical Cancer Research · 2015 · 341 citations · Full text

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

Allyson J. Ocean, Alexander Starodub, Aditya Bardia et al. · Cancer · 2017 · 227 citations · Full text

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters et al. · Journal of Clinical Oncology · 2017 · 181 citations